JP2012525441A5 - - Google Patents

Download PDF

Info

Publication number
JP2012525441A5
JP2012525441A5 JP2012508795A JP2012508795A JP2012525441A5 JP 2012525441 A5 JP2012525441 A5 JP 2012525441A5 JP 2012508795 A JP2012508795 A JP 2012508795A JP 2012508795 A JP2012508795 A JP 2012508795A JP 2012525441 A5 JP2012525441 A5 JP 2012525441A5
Authority
JP
Japan
Prior art keywords
seq
disease
binding protein
syndrome
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012508795A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012525441A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/033246 external-priority patent/WO2010127294A2/en
Publication of JP2012525441A publication Critical patent/JP2012525441A/ja
Publication of JP2012525441A5 publication Critical patent/JP2012525441A5/ja
Withdrawn legal-status Critical Current

Links

JP2012508795A 2009-05-01 2010-04-30 二重可変ドメイン免疫グロブリンおよびこの使用 Withdrawn JP2012525441A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17480009P 2009-05-01 2009-05-01
US61/174,800 2009-05-01
PCT/US2010/033246 WO2010127294A2 (en) 2009-05-01 2010-04-30 Dual variable domain immunoglobulins and uses thereof

Publications (2)

Publication Number Publication Date
JP2012525441A JP2012525441A (ja) 2012-10-22
JP2012525441A5 true JP2012525441A5 (enExample) 2013-07-11

Family

ID=43032808

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012508795A Withdrawn JP2012525441A (ja) 2009-05-01 2010-04-30 二重可変ドメイン免疫グロブリンおよびこの使用

Country Status (14)

Country Link
US (1) US20110008766A1 (enExample)
EP (1) EP2424566A4 (enExample)
JP (1) JP2012525441A (enExample)
KR (1) KR20140014382A (enExample)
CN (1) CN102458459A (enExample)
AU (1) AU2010242840B2 (enExample)
BR (1) BRPI1012195A2 (enExample)
CA (1) CA2760332A1 (enExample)
IL (1) IL216048A0 (enExample)
MX (1) MX2011011670A (enExample)
RU (1) RU2011148918A (enExample)
SG (1) SG175426A1 (enExample)
TW (1) TW201116624A (enExample)
WO (1) WO2010127294A2 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7589180B2 (en) 2001-05-11 2009-09-15 Abbott Laboratories Inc. Specific binding proteins and uses thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
EP2126127B1 (en) * 2007-01-25 2016-09-28 Dana-Farber Cancer Institute, Inc. Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
CA2680854C (en) * 2007-03-15 2017-02-14 Ludwig Institute For Cancer Research Treatment method using egfr antibodies and src inhibitors and related formulations
US9283276B2 (en) 2007-08-14 2016-03-15 Ludwig Institute For Cancer Research Ltd. Monoclonal antibody 175 targeting the EGF receptor and derivatives and uses thereof
JP5646457B2 (ja) 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
PE20100054A1 (es) * 2008-06-03 2010-03-03 Abbott Lab Inmunoglobulina con dominio variable dual
EP3002299A1 (en) * 2008-06-03 2016-04-06 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
MX2010014574A (es) 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
US20100233079A1 (en) * 2008-12-04 2010-09-16 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US8623358B2 (en) 2009-08-29 2014-01-07 Abbvie Inc. Therapeutic DLL4 binding proteins
AR078254A1 (es) 2009-09-01 2011-10-26 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US20110076232A1 (en) * 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
MX2012004415A (es) 2009-10-15 2012-05-08 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2542582A4 (en) 2010-03-02 2013-12-04 Abbvie Inc THERAPEUTIC PROTEINS LINKING TO DLL4
US8735546B2 (en) 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
PH12013500337A1 (en) 2010-08-26 2017-08-23 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
KR20150080033A (ko) 2011-02-08 2015-07-08 애브비 인코포레이티드 골관절염 및 통증의 치료 방법
EP2681242B1 (en) 2011-03-01 2018-01-24 Amgen Inc. Sclerostin and dkk-1 bispecific binding agents
US20140295497A1 (en) 2011-11-30 2014-10-02 Taymar E. Hartman Vectors and host cells comprising a modified sv40 promoter for protein expression
US9120870B2 (en) 2011-12-30 2015-09-01 Abbvie Inc. Dual specific binding proteins directed against IL-13 and IL-17
US9376489B2 (en) 2012-09-07 2016-06-28 Novartis Ag IL-18 binding molecules
WO2014037811A2 (en) 2012-09-07 2014-03-13 The Governors Of The University Of Alberta Methods and compositions for diagnosis of inflammatory liver disease
AU2013337775B2 (en) 2012-11-01 2017-03-30 Abbvie Inc. Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof
EP2970459A2 (en) 2013-03-15 2016-01-20 AbbVie Inc. Dual specific binding proteins directed against il-1beta and il-17
GB201308271D0 (en) * 2013-05-08 2013-06-12 Nat Univ Ireland Semi-automated whole blood immuno potency assay
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
US9822172B2 (en) 2013-11-06 2017-11-21 Astute Medical, Inc. Assays for IGFBP7 having improved performance in biological samples
CA2935423C (en) 2014-01-24 2023-11-07 Dana-Farber Cancer Institute, Inc. Antibody molecules to pd-1 and uses thereof
AU2015210750B2 (en) 2014-01-31 2020-08-20 Children's Medical Center Corporation Antibody molecules to TIM-3 and uses thereof
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
WO2016040882A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of egfr inhibitors
WO2016079219A1 (en) * 2014-11-19 2016-05-26 Koninklijke Philips N.V. Diagnostic method employing hnl
ES2571441B1 (es) * 2014-11-24 2017-03-07 Instituto De Investigación Sanitaria - Fundación Jiménez Díaz Uso de moléculas que reducen los niveles de lipocalina-2 para la fabricación de un medicamento para el tratamiento de aneurisma aórtico abdominal (AAA)
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
ES2878188T3 (es) 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
EP3684801A1 (en) * 2017-09-22 2020-07-29 H. Hoffnabb-La Roche Ag Multivalent mono- or bispecific recombinant antibodies for analytic purpose
CN109678958B (zh) * 2019-01-31 2022-03-18 重庆探生科技有限公司 一种人NT-proBNP特异性重组羊单克隆抗体及其制备方法和应用
WO2022020680A1 (en) 2020-07-23 2022-01-27 Othair Prothena Limited Anti-abeta antibodies
WO2023278520A1 (en) * 2021-06-30 2023-01-05 Board Of Regents, The University Of Texas System Polypeptides targeting cd70-positive cancers
CN114366853B (zh) * 2022-01-20 2023-04-14 华东理工大学 一种高诱骨活性牙种植体涂层及其制备方法
CN119708212A (zh) * 2023-09-21 2025-03-28 东莞市朋志生物科技有限公司 检测hiv p24的抗体对、试剂和方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2134212T3 (es) * 1991-04-25 1999-10-01 Chugai Pharmaceutical Co Ltd Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano.
DE69303494T2 (de) * 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US6491916B1 (en) * 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
KR100940380B1 (ko) * 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6818392B2 (en) * 2000-12-06 2004-11-16 Abbott Laboratories Monoclonal antibodies to human immunodeficiency virus and uses thereof
EP2340849A1 (en) * 2001-05-30 2011-07-06 Genentech, Inc. Anti-NGF antibodies for the treatment of various disorders
BR0213078A (pt) * 2001-09-25 2004-11-23 Fujisawa Pharmaceutical Co Anticorpo recombinante anti-osteopontina e uso do mesmo
NZ544797A (en) * 2003-07-18 2011-04-29 Amgen Fremont Inc Specific antibodies that bind HGF and neutralise binding of HGF to met
CN1871259A (zh) * 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
SG156672A1 (en) * 2004-10-22 2009-11-26 Amgen Inc Methods for refolding of recombinant antibodies
AU2006216291B2 (en) * 2005-02-27 2011-01-27 Institute For Antibodies Co., Ltd. Anti-IgSF4 antibody and utilization of the same
MX2007011735A (es) * 2005-03-24 2008-03-14 Thrombogenics Nv Anticuerpo anti-plgf novedoso.
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP5364870B2 (ja) * 2005-08-19 2013-12-11 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
AR061246A1 (es) * 2006-06-06 2008-08-13 Genentech Inc Anticuerpos anti- dill4 y metodos que los usan
US20080112888A1 (en) * 2006-06-30 2008-05-15 Schering Corporation Igfbp2 biomarker
PL3339445T3 (pl) * 2006-09-08 2020-12-14 Abbvie Bahamas Ltd. Białka wiążące interleukinę 13
GB0708002D0 (en) * 2007-04-25 2007-06-06 Univ Sheffield Antibodies
EP1997832A1 (en) * 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
WO2009003142A1 (en) * 2007-06-27 2008-12-31 The Board Of Trustees Of The Leland, Stanford Junior University Beta2-microglobulin and c reactive protein (crp) as biomarkers for peripheral artery disease
WO2009020654A1 (en) * 2007-08-08 2009-02-12 Abbott Laboratories Compositions and methods for crystallizing antibodies
ES2628395T3 (es) * 2007-08-15 2017-08-02 Bayer Pharma Aktiengesellschaft Anticuerpo regulado por proteasa
EP2235053A1 (en) * 2007-10-19 2010-10-06 Abbott Laboratories Glycosylated mammalian ngal and use thereof
US9273136B2 (en) * 2008-08-04 2016-03-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human anti-human NKG2D monoclonal antibodies
BRPI0919426A2 (pt) * 2008-09-30 2015-12-15 Abbott Lab métodos melhorado de exposição de rna
JP2014500712A (ja) * 2010-11-02 2014-01-16 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
US20120263722A1 (en) * 2010-11-04 2012-10-18 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
US9120870B2 (en) * 2011-12-30 2015-09-01 Abbvie Inc. Dual specific binding proteins directed against IL-13 and IL-17
UY34556A (es) * 2011-12-30 2013-07-31 Abbvie Inc Dominio variable dual de inmunoglobulinas y sus usos
WO2013101993A2 (en) * 2011-12-30 2013-07-04 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof

Similar Documents

Publication Publication Date Title
JP2013507969A5 (enExample)
JP2013507928A5 (enExample)
JP2013503607A5 (enExample)
JP2013509189A5 (enExample)
JP2013500721A5 (enExample)
JP2013537415A5 (enExample)
JP2011523853A5 (enExample)
JP2012500621A5 (enExample)
JP2011523400A5 (enExample)
JP2014504860A5 (enExample)
JP2013539364A5 (enExample)
JP2011527580A5 (enExample)
JP2012525155A5 (enExample)
RU2013133811A (ru) Иммуноглобулины с двойными вариабельными доменами и их применения
RU2011104348A (ru) Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение
RU2015143833A (ru) СВЯЗЫВАЮЩИЕ БЕЛКИ С ДВОЙНОЙ СПЕЦИФИЧНОСТЬЮ, НАПРАВЛЕННЫЕ ПРОТИВ TNFα
JP2012519708A5 (enExample)
RU2012107526A (ru) Иммуноглобулины с двумя вариабельными доменами и их применение
RU2012121189A (ru) Иммуноглобулины с двумя вариабельными доменами и их применение
RU2013109275A (ru) Иммуноглобулины с двумя вариабельными доменами и их применение
RU2010153580A (ru) Иммуноглобулины с двумя вариабельными доменами и их применение
WO2012027570A4 (en) Dual variable domain immunoglobulins and uses thereof
WO2011047262A4 (en) Dual variable domain immunoglobulins and uses thereof
RU2012112550A (ru) Иммуноглобулины с двумя вариабельными доменами и их применение
RU2013105338A (ru) Иммуноглобулины с двумя вариабельными доменами и их применение